QuidelOrtho Corp (QDEL) stock
QDELNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends January 1
Financials through Q3 FY2026, quarter ended Sep 27, 2026Last filing: 10-Q on Nov 4, 2026Score 6/3063% below fair value
$9.87−0.34 (-3.33%)
Close on Nov 17, 2026Market cap $676.84MP/E –Yield –
QuidelOrtho total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
QuidelOrtho's total debt was $2.94B at Sep 27, 2026. For fiscal 2025 it was $2.65B, up 6.7% from the year before. The highest annual figure on record is $2.65B in fiscal 2025.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $2.65B | +6.7% |
| FY2024 | Dec 29, 2024 | $2.48B | +2.8% |
| FY2023 | Dec 31, 2023 | $2.41B | -8.5% |
| FY2022 | Jan 1, 2023 | $2.64B | +263730.0% |
| FY2021 | Jan 2, 2022 | $1.00M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 27, 2026 | $2.94B | +10.5% |
| Q2 FY2026 | Jun 28, 2026 | $2.89B | +10.9% |
| Q1 FY2026 | Mar 29, 2026 | $2.69B | +7.5% |
| Q4 FY2025 | Dec 28, 2025 | $2.65B | +6.7% |
| Q3 FY2025 | Sep 28, 2025 | $2.66B | +4.3% |
| Q2 FY2025 | Jun 29, 2025 | $2.61B | +1.7% |
| Q1 FY2025 | Mar 30, 2025 | $2.50B | +4.1% |
| Q4 FY2024 | Dec 29, 2024 | $2.48B | +2.8% |
| Q3 FY2024 | Sep 29, 2024 | $2.55B | -4.1% |
| Q2 FY2024 | Jun 30, 2024 | $2.56B | -5.9% |
| Q1 FY2024 | Mar 31, 2024 | $2.40B | -14.0% |
| Q4 FY2023 | Dec 31, 2023 | $2.41B | -8.5% |
| Q3 FY2023 | Oct 1, 2023 | $2.66B | -8.2% |
| Q2 FY2023 | Jul 2, 2023 | $2.72B | -7.7% |
| Q1 FY2023 | Apr 2, 2023 | $2.79B | +279360.0% |
| Q4 FY2022 | Jan 1, 2023 | $2.64B | – |
| Q3 FY2022 | Oct 2, 2022 | $2.90B | – |
| Q2 FY2022 | Jul 3, 2022 | $2.95B | – |
| Q4 FY2021 | Jan 2, 2022 | $1.00M | – |
See a number that looks wrong?